Please add the following claims:

35. (New) A method for treating a patient suffering from hypermotilinemia comprising administering to said patient an effective amount of a compound according to claim 1.

36. (New) A method for suppressing gastrointestinal motility in a patient suffering therefrom comprising administering to said patient an effective amount of a compound according to claim 1.

REMARKS

Claims 1-25 and 28-36 presently appear in this case. The above amendments to the specification are being made in order to correct several self-evident typographical errors. The amendments to the claims are being made in order to add new claims.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned **"Version with Markings to Show Changes Made."**

Favorable consideration is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: _____
Roger L. Browdy
Registration No. 25,618

RLB:wrd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528

Version with markings to show changes

IN THE SPECIFICATION

A paragraph was added after the title.

Page 42, please amend Table A-8 as follows:

Table A-8

Example No.	Structural formula or chemical name
126	N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH$_2$OH
127	Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH$_2$OH
128	N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH$_2$OH
129	N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH$_2$OH
130	Phe(4-F)-N-Et-Val-N-Et-Tyr(3-tBu)-NHCH$_2$OH
131	N-Me-Phe(4-F)-N-Et-Val-N-Et-Tyr(3-tBu)-NHCH$_2$OH
132	Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH$_2$OH
133	(2S)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N-methylpropanolyamino]-N-((1S)-1-{[3-(tert-butyl)-4-hydroxyphenyl]methyl}-2-morpholin-4-yl-2-oxoethyl)-3-methyl-N-methylbutanamide
134	(2S)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N-methylpropanolyamino]-N-((1S)-1-{[3-(tert-butyl)-4-hydroxyphenyl]methyl}-2-[4-(methylsulfonyl)piperazinyl]-2-oxoethyl)-3-methyl-N-methylbutanamide
135	ethyl 2-[4-((2S)-2-{(2S)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N-methylpropanolyamino]-3,N-dimethylbutanoylamino}-3-[3-(tert-butyl)-4-hydroxyphenyl] **propanoyl propanoly**)piperazinyl]acetate
136	2-[4-((2S)-2-{(2S)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N-methylpropanolyamino]-3,N-dimethylbutanoylamino}-3-[3-(tert-butyl)-4-hydroxyphenyl]**propanoyl propanoly**)piperazinyl]acetic acid
137	Phe(4-F)-N-Me-Val-N-Pr-Tyr(3-tBu)-NH$_2$
138	Phe(4-F)-N-Me-Abu-N-Me-Tyr(3-tBu)-NH$_2$
139	Phe(4-F)-N-Me-D-Abu-N-Me-Tyr(3-tBu)-NH$_2$
140	Phe(4-F)-N-Me-Nva-N-Me-Tyr(3-tBu)-NH$_2$

Page 43, please amend Table A-9 as follows:

Table A-9

Example No.	Structural formula or chemical name
141	Phe(4-F)-N-Me-D-Nva-N-Me-Tyr(3-tBu)-NH
142	Phe(4-F)-N-Me-Ile-N-Me-Tyr(3-tBu)-NH
143	Phe(4-F)-N-Me-D-Ile-N-Me-Tyr(3-tBu)-NH
144	Phe(4-F)-N-Me-Leu-N-Me-Tyr(3-tBu)-NH
145	Phe(4-F)-N-Me-D-Leu-N-Me-Tyr(3-tBu)-NH
146	(2S)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N-**methylpropanoylamino methylpropanolyamino**]-N-{(1S)-2-[3-(tert-butyl)-4-hydroxyphenyl]-1-carbamoylethyl}-N-methylpent-4-enamide
147	(2R)-2-[(2S)-2-amino-3-(4-fluorophenyl)-N-**methylpropanoylamino methylpropanolyamino**]-N-{(1S)-2-[3-(tert-butyl)-4-hydroxyphenyl]-1-carbamoylethyl}-N-methylpent-4-enamide
148	Phe(4-F)-N-Me-Leu(γ-Me)-N-Me-Tyr(3-tBu)-NH
149	Phe(4-F)-N-Me-D-Leu(γ-Me)-N-Me-Tyr(3-tBu)-NH
150	Phe(4-F)-N-Me-Ala(β-CF$_3$)-N-Me-Tyr(3-tBu)-NH
151	Phe(4-F)-N-Me-Chg-N-Me-Tyr(3-tBu)-NH
152	Phe(4-F)-N-Me-D-Chg-N-Me-Tyr(3-tBu)-NH
153	Phe(4-F)-N-Me-Cha-N-Me-Tyr(3-tBu)-NH
154	Phe(4-F)-N-Me-D-Cha-N-Me-Tyr(3-tBu)-NH
155	Phe(4-F)-N-Me-Phe-N-Me-Tyr(3-tBu)-NH
156	Phe(4-F)-N-Me-D-Phe-N-Me-Tyr(3-tBu)-NH
157	Phe(4-F)-N-Me-Phe(4-F)-N-Me-Tyr(3-tBu)-NH
158	Phe(4-F)-N-Me-D-Phe(4-F)-N-Me-Tyr(3-tBu)-NH
159	Phe(4-F)-N-Me-Phe(4-Cl)-N-Me-Tyr(3-tBu)-NH
160	Phe(4-F)-N-Me-D-Phe(4-Cl)-N-Me-Tyr(3-tBu)-NH
161	Phe(4-F)-N-Me-Tyr-N-Me-Tyr(3-tBu)-NH
162	Phe(4-F)-N-Me-D-Tyr-N-Me-Tyr(3-tBu)-NH
163	Phe(4-F)-N-Me-Ala(β-2-thienyl)-N-Me-Tyr(3-tBu)-NH

Page 106, please amend paragraph 1 as follows:

To a solution of 2-(4-benzyloxy-3-t-butylphenyl)-1-cyanomethylethylcarbamic acid benzyl ester (1.38 g, 3.03 mmol) in DMSO (24 ml), potassium carbonate (1.59 g) and 30% hydrogen peroxide (4.0 ml) were added under cooling with ice. After stirring at room temperature for 2 hours, the reaction mixture was mixed with water; the thus formed precipitates were collected by filtration to give 2-(4-benzyloxy-3-t-butylphenyl)-1-carbamidemethylethylcarbamic acid benzyl ester.

Page 257, please amend Table E-7 as follows:

Table E-7

Intermediate T14

(2S)-3-[3-(tert-butyl)-4-hydroxyphenyl]-2-(methylamino)-1-[4-(methylsulfonyl)piperazinyl ~~piperazineyl~~]propane-1-one

IN THE CLAIMS

New claims 35 and 36 were added.